In this study, we found that pralsetinib, a selective RET inhibitor approved for the treatment of RET fusion–positive non-small cell lung cancer and thyroid cancer, exhibits potent anti-tumor activity against TMZ-resistant glioma cells both in vitro and in vivo. The gene discussed is RET; the disease is thyroid gland carcinoma.